Enforcement Report - Week of November 17, 2021
Evonik Industries AG of Germany and METabolic EXplorer (METEX) of France have agreed that Evonik will acquire a technology package from METEX to strengthen its biotechnology platform for amino acids, following an agreement signed today in Paris. The package includes METEX’s entire technology portfolio for the fermentative production of methionine, as well as patents, essential bacteria strains, and the inoLa brand. METEX considers that this agreement will underscore the relevance of METEX’s alternative technologies and will strengthen its ability to commercialise its other technologies. The transaction still requires authorisation of the Evonik committees.
Co-amorphization has recently been shown to be a promising approach for stabilizing amorphous drugs and improving the dissolution rate of poorly water-soluble drugs. In this study, three basic amino acids were chosen as small molecular weight excipients to interact with the drug to form co-amorphous combinations. The co-amorphous combinations of valsartan (VAL) with l-histidine, l-arginine, and l-lysine were prepared by vibrational ball milling. Solid-state characterization with X-ray powder diffraction and differential scanning calorimetry (DSC) revealed that all of the co-amorphous mixtures were homogeneous. The molecular interactions of the co-amorphous mixtures were investigated through the glass transition temperature (Tg) in the DSC measurements and Fourier transform infrared spectroscopy.
Recall: Baxter`s Clinimix (2015-06-19)